China's Sinopharm to test potential Covid-19 vaccine in Brazil Thursday, 30 Jul 2020 08:37 AM MYT
The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong March 29, 2016. — Reuters pic The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong March 29, 2016. — Reuters pic RIO DE JANEIRO, July 30 — Chinese drug company Sinopharm and Parana state have agreed to launch the fourth major Covid-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said yesterday.
A trial by Sinopharm would join Phase III trials already announced in Brazil by AstraZeneca, Sinovac Biotech and a Pfizer partnership with BioNTech.
Jorge Callado, head of the Parana Technology Institute (Tecpar), said they would soon finalize their proposal and submit it for approval with federal health regulator Anvisa.
Brazil's Covid-19 outbreak, the world's worst outside the United States, has made it global testing ground for potential vaccines.
Sinopharm's candidate vaccine is already being tested in the United Arab Emirates with 15,000 volunteers.
Parana is also in talks with Russian researchers about producing their potential vaccine, the state government said in a statement, adding that Governor Ratinho Júnior would soon meet with Russia's ambassador to Brazil.
Russians have also contacted Sao Paulo's Butantan Institute to discuss testing their vaccine, the institute's director told reporters on Wednesday. — Reuters
please explain how titijaya will benefit from sinopham vaccine ?
"Meanwhile, TRSB will be responsible to provide infrastructure, land and facilities for medical industry operators recommended by Sinopharm Group or SMEQ. The Agreement shall remain in force for a period of five years and subject to a renewable period of five years. The terms of the renewable period shall be subject to further agreement between TRSB and SMEQ."
Furthermore it was stated the Agreement WILL NOT HAVE a material effect on Titijaya’s FY20 net earnings. We believe the JV is still in early stage, therefore we make no changes to our earnings forecasts. Maintain HOLD with an unchanged fair value of RM0.28
At any time during the exercise period indicated above,(i) every 1 ICPS and cash payment of RM0.7425 can be converted into 1 new Subdivided Share; or(ii) every 10 ICPS, without any cash, can be converted into 1 new Subdivided Share
so if u buy 10 ICPS you can get 1 share... ie 10x0.055 = 55 sen, and u can get 1 titijaya share worth 68 sen
maybe next year once sinopham got build new facility for vaccine, then titijaya will get the deal... the agreement is for 5 years.. they only have 1 facitliy in wuhan, maybe msia facility will be done by titjaya?
supersinginvestor Hey pang idiot. U talk 1 month now only limit up. I said in the morning n limit up. I told u idiot. It made the list only today in the morning after the wave. Now going to rm 3 10/08/2020 4:44 PM
HELLO SOHAI.... INVESTOR, PLEASE GO TITIJAYA READ MY CIMMENT DURING THE WEEKEND.
LAST WEEK ALREADY KNOW LIMIT UP LIAO..
YOUR LIST INCLUDED TOP GLOVE, KOSSAN ALL THESE OVER GORENG STOCK.. LIMIT UP KAH!!?????
TITIJAYA SON.. At any time during the exercise period indicated above,(i) every 1 ICPS and cash payment of RM0.7425 can be converted into 1 new Subdivided Share; or(ii) every 10 ICPS, without any cash, can be converted into 1 new Subdivided Share
So since now that titijaya mother has go above 0.7425, the son will be very interesting.. almost like a warrant and can move faster, since the conversion price is 0.7425 with 1 son.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
BobbyAxelrod
73 posts
Posted by BobbyAxelrod > 2020-08-10 11:54 | Report Abuse
China's Sinopharm to test potential Covid-19 vaccine in Brazil
Thursday, 30 Jul 2020 08:37 AM MYT
The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong March 29, 2016. — Reuters pic
The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong March 29, 2016. — Reuters pic
RIO DE JANEIRO, July 30 — Chinese drug company Sinopharm and Parana state have agreed to launch the fourth major Covid-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said yesterday.
A trial by Sinopharm would join Phase III trials already announced in Brazil by AstraZeneca, Sinovac Biotech and a Pfizer partnership with BioNTech.
Jorge Callado, head of the Parana Technology Institute (Tecpar), said they would soon finalize their proposal and submit it for approval with federal health regulator Anvisa.
Brazil's Covid-19 outbreak, the world's worst outside the United States, has made it global testing ground for potential vaccines.
Sinopharm's candidate vaccine is already being tested in the United Arab Emirates with 15,000 volunteers.
Parana is also in talks with Russian researchers about producing their potential vaccine, the state government said in a statement, adding that Governor Ratinho Júnior would soon meet with Russia's ambassador to Brazil.
Russians have also contacted Sao Paulo's Butantan Institute to discuss testing their vaccine, the institute's director told reporters on Wednesday. — Reuters